We are live on ! Find out more
KLRS

Kalaris Therapeutics
KLRS

75 hedge funds and large institutions have $600M invested in Kalaris Therapeutics in 2021 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 38 increasing their positions, 10 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

11,807% more call options, than puts

Call options by funds: $5.24M | Put options by funds: $44K

280% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 10

40% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 10

6% more funds holding

Funds holding: 71 → 75 (+4)

0.22% more ownership

Funds ownership: 1.56% → 1.78% (+0.22%)

30% less capital invested

Capital invested by funds: $854M → $600M (-$254M)

Holders
75
Holders Change
+4
Holders Change %
+5.63%
% of All Funds
1.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
38
Reduced
10
Closed
10
Calls
$5.24M
Puts
$44K
Net Calls
+$5.2M
Net Calls Change
+$5.18M

Top Buyers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
+$29.6M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$28.4M
3
BlackRock
BlackRock
New York
+$20.4M
4
JP Morgan Chase
JP Morgan Chase
New York
+$17.9M
5
Goldman Sachs
Goldman Sachs
New York
+$9.14M

Top Sellers

Rank Fund Capital Flow
1
RG
Redmile Group
California
-$14M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$7.99M
3
TG
TCW Group
California
-$6.41M
4
First Trust Advisors
First Trust Advisors
Illinois
-$2.61M
5
Norges Bank
Norges Bank
Norway
-$1.92M
Name Holding Trade Value Shares
Change 		Change in
Stake
Rafferty Asset Management
26
Rafferty Asset Management
New York
$1.74M +$2.48M +2,946 +999%
Morgan Stanley
27
Morgan Stanley
New York
$1.71M +$1.05M +1,250 +65%
UBS Group
28
UBS Group
Switzerland
$1.68M +$2.61M +3,111 +25,925%
Susquehanna International Group
29
Susquehanna International Group
Pennsylvania
$1.67M +$2.15M +2,554 +459%
D.E. Shaw & Co
30
D.E. Shaw & Co
New York
$1.44M +$2.25M +2,681 New
CSS
31
Cubist Systematic Strategies
Connecticut
$1.36M +$2.13M +2,536 New
California State Teachers Retirement System (CalSTRS)
32
California State Teachers Retirement System (CalSTRS)
California
$1.04M +$640K +762 +65%
TG
33
TCW Group
California
$951K -$6.41M -7,629 -81%
Two Sigma Investments
34
Two Sigma Investments
New York
$838K +$1.31M +1,557 New
California Public Employees Retirement System
35
California Public Employees Retirement System
California
$812K -$116K -138 -8%
Bank of America
36
Bank of America
North Carolina
$738K +$1.05M +1,248 +1,023%
Swiss National Bank
37
Swiss National Bank
Switzerland
$688K – – –
RhumbLine Advisers
38
RhumbLine Advisers
Massachusetts
$675K +$328K +390 +45%
CM
39
Caption Management
Oklahoma
$656K +$1.02M +1,217 New
Deutsche Bank
40
Deutsche Bank
Germany
$613K +$276K +329 +41%
State of Wisconsin Investment Board
41
State of Wisconsin Investment Board
Wisconsin
$592K – – –
LCM
42
Laurion Capital Management
New York
$585K – – –
Osaic Holdings
43
Osaic Holdings
Arizona
$584K +$911K +1,084 New
FFN
44
Focus Financial Network
Minnesota
$584K +$911K +1,084 New
SAM
45
Sectoral Asset Management
Quebec, Canada
$502K +$428K +509 +120%
New York State Common Retirement Fund
46
New York State Common Retirement Fund
New York
$498K +$182K +217 +31%
DekaBank Deutsche Girozentrale
47
DekaBank Deutsche Girozentrale
Germany
$422K – – –
Manulife (Manufacturers Life Insurance)
48
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$397K +$219K +260 +54%
ProShare Advisors
49
ProShare Advisors
Maryland
$396K +$106K +126 +21%
EAM
50
Erste Asset Management
Austria
$364K – – –
1
2
3 4

KLRS Hedge Fund Activity: Q1 2021 in Review

75 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Kalaris Therapeutics (KLRS) for Q1 2021, worth a combined $600M — down 30% from $854M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new KLRS positions and 10 closed out — a net gain of 4 holders — while 38 added to existing stakes and 10 trimmed.

The largest buyer was State Street, adding an estimated $29.6M. The largest seller was Redmile Group, cutting an estimated $14M.

  • 75 institutional investors held Kalaris Therapeutics (KLRS) as of Q1 2021, up from 71 in Q4 2020.
  • Funds reported $600M of Kalaris Therapeutics stock for Q1 2021, down 30% quarter-over-quarter.
  • 14 funds opened new Kalaris Therapeutics positions in Q1 2021 and 10 closed out, a net change of +4 holders.
  • The largest Kalaris Therapeutics buyer in Q1 2021 was State Street, an estimated $29.6M added.
  • The largest Kalaris Therapeutics seller in Q1 2021 was Redmile Group, an estimated $14M sold.

Based on aggregated 13F filings for Q1 2021.